At a glance: peptide merchant accounts
- Typical rates (2026): 3.25% to 3.99% per transaction, depending on volume, risk and chargeback history
- Rolling reserve: often 5% to 10% of sales, held about 90 to 180 days and released on a schedule
- Typical approval time: about 5 to 10 business days once your application is complete
- Have ready: Certificates of Analysis, product labels, supplier details, government ID for each owner, business registration documents, and recent bank statements
- What underwriters check: products, buyers and marketing that genuinely match research-only sales, research-only labels, buyer verification and clean supplier records
Get a free quoteor call (888) 542-4147
A peptide merchant account is a high-risk merchant account that lets businesses selling research peptides, or licensed pharmacies dispensing peptides on prescription, accept credit and debit cards. Many acquirers review the category closely, because the FDA judges products by intended use and the card networks prohibit selling products that imply prescription drug effects.
Paymotile is free to apply and works to match eligible peptide businesses with processors and acquiring banks that review the category case by case. If your customers buy peptides for personal use, removing website language will not make the business eligible. Start your free application. This page explains payment and compliance rules only. It is not medical or legal advice and says nothing about whether any peptide is safe or effective. For other industries, see our high risk merchant account guide.
Why are peptide sellers considered high risk?
Peptide sellers are high risk because the line between a lawful research chemical and an unapproved drug depends on how the product is marketed, not only on what is in the vial. One product page, affiliate post or bundled syringe kit can turn a “research” product into an unapproved drug in the FDA’s eyes.
The specific risk drivers underwriters weigh are:
- Regulatory exposure: the FDA has issued warning letters to online peptide sellers in 2026, treating “research use only” products as unapproved new drugs.
- Card network rules: Visa prohibits card acceptance for products that “claim or imply a similar efficacy as prescription drugs,” and Mastercard’s BRAM program restricts illegal or brand-damaging transactions.
- Fast-moving status: the FDA’s compounding lists, an advisory committee review and a draft HHS policy all touched popular peptides in 2026, so a bank cannot rely on last year’s assessment.
- Disputes: buyers who expected results, or who bought with a stolen card, file chargebacks, and online sales are card-not-present.
Is it legal to sell research peptides labeled “not for human consumption”?
A research-only label alone does not protect you. The FDA decides what a product is by its intended use, which it reads from your whole website, marketing and product mix. If those show the product is meant for people, the FDA can treat it as an unapproved new drug despite the label.
The FDA’s intended use regulation, 21 CFR 201.128, lets the agency look at labeling claims, advertising and the circumstances of sale. Two 2026 warning letters show how this works:
- Gram Peptides (March 31, 2026): the FDA’s warning letter said evidence from the company’s website established that its products were intended to be drugs for human use, despite “Research Use Only” labeling. It cited product-page statements about body weight and appetite, and said selling bacteriostatic water alongside the peptides showed they were meant to be combined for injection.
- Peptide Partners LLC (August 24, 2026): the FDA’s warning letter made the same finding for products labeled “for research use only,” citing disease-related statements on product pages and a reconstitution solution sold with the peptides. Both letters cited introducing unapproved new drugs into interstate commerce.
Underwriters typically look for the same signals the FDA cited: product-page health claims and injection or reconstitution supplies sold with the peptides. Relabeling a product or rewording a site does not cure marketing for human use.
What is the FDA category 2 list, and what changed in 2026?
Category 2 is the FDA’s list of bulk drug substances nominated for pharmacy compounding that may present significant safety risks. Several popular peptides, including BPC-157 and TB-500, are now listed by the FDA as nominated but withdrawn from category 2, but that did not make them approved drugs or legal research-chemical products for human use.
Under section 503A of the Food, Drug, and Cosmetic Act (21 U.S.C. 353a), licensed pharmacies and physicians may compound drugs for individual patients from bulk substances that meet certain conditions. While the official 503A bulks list is developed, the FDA sorts nominated substances into categories. The key developments:
- Withdrawn from category 2: the FDA’s safety risks page (current as of April 22, 2026) lists AOD-9604, BPC-157, CJC-1295, melanotan II, TB-500 and others as substances previously in category 2 whose nominations were withdrawn. For BPC-157, it says the FDA lacks sufficient information to know whether the drug would cause harm when administered to humans.
- Current category 2: the FDA’s 503A categories list (updated May 14, 2026) still places ibutamoren mesylate and kisspeptin-10 in category 2.
- Advisory committee: the FDA’s Pharmacy Compounding Advisory Committee met July 23 and 24, 2026 to discuss BPC-157, TB-500, KPV, MOTs-C, emideltide, Semax and Epitalon for the 503A bulks list. Committee votes are advisory, not binding.
- HHS enforcement policy: on October 30, 2026 HHS published a draft enforcement discretion policy (comment period ending November 13, 2026) saying it does not intend to take enforcement action against state-licensed pharmacies, federal facilities or licensed physicians compounding with listed peptides while rulemaking continues. The notice says the policy is not binding and may be revisited if a safety signal arises.
None of this covers a website selling vials directly to consumers. The HHS policy is limited to compounding by licensed pharmacies, federal facilities and physicians, and compounded drugs are still not FDA-approved.
| Seller type | How the product reaches buyers | How underwriters usually view it |
|---|---|---|
| State-licensed compounding pharmacy | Patient-specific prescriptions | Pharmacy account: licenses, prescriptions and card network pharmacy rules apply |
| Telehealth brand with a partner pharmacy | Prescriber visit, then pharmacy dispensing | Telehealth and pharmacy underwriting; drug marketing reviewed closely |
| Research chemical supplier | Sold to labs and researchers, labeled not for human use | Case by case; site language, buyers and product mix decide it |
| Consumer “peptide” retailer with dosing content | Sold to the public for personal use | Generally declined: matches the FDA’s warning-letter pattern |
What do Visa and Mastercard rules say about peptides?
Neither network names peptides, but both rules reach them. Visa prohibits card acceptance for products that claim or imply efficacy similar to prescription drugs, regardless of claims of legality. Mastercard’s BRAM program restricts illegal or brand-damaging transactions. Ask your acquirer how it applies both rules to your product list.
The Visa Core Rules (October 24, 2026 edition) require acquirers to ensure merchants do not accept cards for “the purchase of products that claim or imply a similar efficacy as prescription drugs, controlled substances, or recreational/street drugs, irrespective of claims of legality.” Violation may result in termination of the merchant. A peptide marketed as a cheaper alternative to a prescription weight loss drug would likely be treated as falling under that rule, whatever the label says.
Mastercard’s published policy describes its Business Risk Assessment and Mitigation (BRAM) program as restricting transactions that are illegal or that could damage the Mastercard brand. A terminated merchant can be listed on the MATCH list, which makes the next account much harder to get.
What do underwriters check for a peptide merchant account?
Underwriters review the whole storefront, not just the application. They want third-party lab testing, research-only labels, site copy with no human-use or health language, buyer verification, and suppliers they can identify. The more of your business that sits in the lower-risk column below, the better your odds.
| Factor | Lower risk | Higher risk |
|---|---|---|
| Product claims | Chemical names, purity, specifications only | Benefits, “results,” weight loss, healing or anti-aging language |
| Usage content | None | Dosing charts, protocols, reconstitution or injection guides |
| Product mix | Research compounds and lab supplies | Bundled bacteriostatic water, syringes or “starter kits” |
| Lab testing | Batch-matched Certificates of Analysis from independent labs | No COAs, or generic COAs not tied to a batch |
| Labels | Research-only and not-for-human-use statements on vials and pages | Labels that conflict with site or social media copy |
| Buyers | Age verification, research attestation at checkout, institutional buyers | No checks, influencer and affiliate traffic |
| Product names | Accurate chemical names | Names that echo brand-name prescription drugs |
Audit affiliate pages, social accounts and customer reviews you display, since underwriters review them too.
How is a peptide account different from a nutraceutical or pharmacy account?
A nutraceutical account covers dietary supplements sold for human use under supplement law. A pharmacy account covers licensed sale of prescription drugs. Research peptides fit neither: they are sold as non-human research chemicals, so the account depends on keeping every part of the business consistent with genuine research-only sales.
If your products are dietary supplements, such as collagen peptides sold as food, see our nutraceutical merchant account guide. If you are a licensed pharmacy or telehealth practice dispensing peptides on prescription, see our telemedicine and pharmacy merchant account guide. Mixing models on one site can complicate underwriting, so keep research, supplement and prescription lines on separate storefronts and disclose each one.
What documents do you need to apply?
Bring standard business and owner documents plus product evidence: COAs, label images, supplier details and screenshots of checkout. Underwriters compare these to your live site, so make sure the two match. A complete, consistent file is the fastest route to approval.
- Business registration documents, EIN and a business bank account
- Government ID for each owner
- Recent bank statements, plus recent processing statements if you have them
- Full product list with chemical names and batch-matched Certificates of Analysis
- Photos of vial labels and packaging
- Supplier and manufacturer details, including country of origin
- Screenshots of age verification and research attestation at checkout
- Website terms, refund policy, privacy policy and contact details
- Any prior termination letter and a chargeback summary, if applicable
What does a peptide merchant account cost?
As of 2026, typical high-risk rates run 3.25% to 3.99% per transaction, depending on volume, risk and chargeback history. Expect a rolling reserve of about 5% to 10% of sales, held about 90 to 180 days. Get every fee and reserve term in writing before you sign.
A rolling reserve holds part of each day’s sales against refunds and chargebacks. Keep combined fraud and disputes as low as possible. Since April 1, 2026, Visa’s VAMP program flags a US merchant as excessive at 1.5% or higher, counting fraud and disputes over settled card-not-present transactions, with at least 1,500 combined reports in a month. See our VAMP explainer and chargeback prevention page.
How do you apply through Paymotile?
Apply once, free. Paymotile is a high-risk merchant account agent, not a bank: we review your site and file for gaps, then match your business with processors and acquiring banks that review peptide sellers. Approval is never guaranteed, and some business models will not qualify anywhere.
- Complete the free application or call (888) 542-4147.
- Describe your model: research supplier, compounding pharmacy or telehealth partner.
- Confirm your business really is research-only: products, buyers and marketing (site, social, affiliates) must all match that model. Paymotile cannot place sellers whose products are meant for human use.
- Send COAs, labels, supplier details and checkout screenshots.
- Review the offer, sign, integrate your gateway and start processing.
If Stripe, PayPal or Square closed your account, bring the termination notice and fix the site issues before reapplying.
Peptide merchant account FAQ
Will Stripe, PayPal or Square process peptide sales?
Payment aggregators approve accounts automatically and review them later, and peptide sellers are frequently closed after review. A dedicated high-risk account is underwritten before you process, so the bank knows your products up front.
Does a “not for human consumption” label make my store compliant?
No. The FDA reads intended use from your whole site and marketing. In 2026 warning letters it disregarded research-only labels when product pages and bundled supplies suggested human use.
Did BPC-157 become legal in 2026?
Its nomination was withdrawn from category 2 and an FDA advisory committee reviewed it in July 2026. In October 2026 HHS also published a draft enforcement discretion policy for compounding certain peptides by licensed pharmacies and physicians. None of that approves BPC-157 as a drug or authorizes selling it to consumers.
Can I sell GLP-1 peptides as research chemicals?
Expect most acquirers to decline. Both 2026 warning letters cited above involved GLP-1 class products such as tirzepatide or retatrutide, and Visa’s rules bar products that imply prescription drug effects.
How long does approval take?
About 5 to 10 business days once the application is complete. Site copy that conflicts with your labels can delay underwriting.
Related guides: what a merchant account is, merchant account fees, the Visa VAMP chargeback threshold and the MATCH list.
Sources
Statistics and legal references in this guide come from the sources below. We review them regularly and update the page when newer data is published.
- Electronic Code of Federal Regulations, 21 CFR 201.128, Meaning of “intended uses”.
- U.S. Food and Drug Administration, Warning Letter to Gram Peptides, 721806 (March 31, 2026).
- U.S. Food and Drug Administration, Warning Letter to Peptide Partners LLC, 735063 (August 24, 2026).
- Legal Information Institute, 21 U.S.C. 353a, Pharmacy compounding.
- U.S. Food and Drug Administration, Certain Bulk Drug Substances for Use in Compounding that May Present Significant Safety Risks (content current as of April 22, 2026).
- U.S. Food and Drug Administration, Bulk Drug Substances Nominated for Use in Compounding Under Section 503A of the FD&C Act (updated May 14, 2026).
- U.S. Food and Drug Administration, July 23-24, 2026: Meeting of the Pharmacy Compounding Advisory Committee (content current as of August 6, 2026).
- U.S. Department of Health and Human Services, Enforcement Discretion Policy Regarding 503A Compounding Using Certain Peptide Bulk Drug Substances (October 30, 2026).
- Visa, Visa Core Rules and Visa Product and Service Rules (October 24, 2026).
- Mastercard, Mastercard Anti-Piracy Policy (BRAM program description).
- Visa, Visa Acquirer Monitoring Program Overview (fact sheet) (2025).